SYDNEY, Australia & NEW YORK--(BUSINESS WIRE)--June 8, 2006--Avantogen Limited (“Avantogen”) (ASX:ACU - News), Sydney, Australia and San Diego, CA, and Innovate Oncology, Inc (“Innovate”) (OTCBB:IOVO - News), New York, today announced that 2 abstracts reporting on the evaluation of the use of RP101 in the treatment of patients with pancreatic cancer, were published at this week’s American Society of Medical Oncology (ASCO) Meeting in Atlanta, Georgia.
